Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
暂无分享,去创建一个
C. Rice | M. Nussenzweig | P. Bieniasz | C. Hillyer | A. Gazumyan | D. Robbiani | H. Hoffmann | D. Poston | Y. Weisblum | E. Michailidis | L. Luchsinger | T. Hatziioannou | C. Gaebler | F. Muecksch | F. Schmidt | M. Caskey | Zijun Wang | A. Cho | M. Agudelo | M. Cipolla | Fengwen Zhang | Magda Rutkowska | Justin DaSilva | J. C. Lorenzi | Julio C. C. Lorenzi | Larry L. Luchsinger
[1] Suman Mishra,et al. Neutralizing antibody responses to SARS-CoV-2: a population based seroepidemiological analysis in Delhi, India , 2021, medRxiv.
[2] K. To,et al. Serum antibody profile of a patient with COVID-19 reinfection , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] M. Kearney,et al. Low genetic diversity may be an Achilles heel of SARS-CoV-2 , 2020, Proceedings of the National Academy of Sciences.
[4] K. Bishop-Lilly,et al. A Case of Early Re-infection with SARS-CoV-2 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] L. Gieselmann,et al. Erratum: Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients (Cell (2020) 182(4) (843–854.e12), (S0092867420308217), (10.1016/j.cell.2020.06.044)) , 2020 .
[6] P. Bieniasz,et al. Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients , 2020, Journal of Clinical Microbiology.
[7] Sarah K. Hilton,et al. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition , 2020, bioRxiv.
[8] C. Rice,et al. Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro , 2020, bioRxiv.
[9] P. Maes,et al. Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] L. Gieselmann,et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients , 2020, Cell.
[11] Bethany L. Dearlove,et al. A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants , 2020, Proceedings of the National Academy of Sciences.
[12] K. To,et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] G. Ippolito,et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes , 2020, Science.
[14] J. Sodroski,et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike , 2020, Nature.
[15] C. Rice,et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses , 2020, The Journal of experimental medicine.
[16] Edward C. Holmes,et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology , 2020, Nature Microbiology.
[17] Lisa E. Gralinski,et al. Potently neutralizing and protective human antibodies against SARS-CoV-2 , 2020, Nature.
[18] D. Burton,et al. Structural basis of a shared antibody response to SARS-CoV-2 , 2020, Science.
[19] S. Rowland-Jones,et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus , 2020, Cell.
[20] M. Nussenzweig,et al. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies , 2020, Cell.
[21] David Robertson,et al. CoV-GLUE: A Web Application for Tracking SARS-CoV-2 Genomic Variation , 2020 .
[22] J. Sodroski,et al. Potent Neutralizing Antibodies Directed to Multiple Epitopes on SARS-CoV-2 Spike , 2020, bioRxiv.
[23] D. Devine,et al. Clinical use of Convalescent Plasma in the COVID‐19 pandemic: a transfusion‐focussed gap analysis with recommendations for future research priorities , 2020, Vox sanguinis.
[24] G. Atwal,et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies , 2020, Science.
[25] D. Burton,et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.
[26] J. Dye,et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies , 2020, Science.
[27] R. Welsh,et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail , 2020, Science.
[28] C. Rice,et al. Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.
[29] L. Gieselmann,et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients , 2020, Cell.
[30] P. Bieniasz,et al. Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19 Patients , 2020, medRxiv.
[31] C. Rice,et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses , 2020, bioRxiv.
[32] L. Stamatatos,et al. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation , 2020, Immunity.
[33] Ilya J. Finkelstein,et al. Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes , 2020, bioRxiv.
[34] M. Nussenzweig,et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies , 2020, bioRxiv.
[35] William J. Liu,et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 , 2020, Nature.
[36] Linqi Zhang,et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, Nature.
[37] Lisa E. Gralinski,et al. Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals , 2020, bioRxiv.
[38] X. Xie,et al. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells , 2020, Cell.
[39] C. Rice,et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals , 2020, bioRxiv.
[40] L. Stamatatos,et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual , 2020, bioRxiv.
[41] M. V. van Breemen,et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.
[42] Qiang Zhou,et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability , 2020, bioRxiv.
[43] F. Gao,et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 , 2020, Science.
[44] F. Balloux,et al. Emergence of genomic diversity and recurrent mutations in SARS-CoV-2 , 2020, Infection, Genetics and Evolution.
[45] P. Kellam,et al. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection , 2020, The Journal of general virology.
[46] J. Zhao,et al. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor , 2020, Cellular & Molecular Immunology.
[47] Wayne T. Nicholson,et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. , 2020, The Journal of clinical investigation.
[48] P. Vollmar,et al. Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.
[49] Y. Wen,et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications , 2020, medRxiv.
[50] Lei Liu,et al. Potent human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, bioRxiv.
[51] Qiang Zhou,et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 , 2020, Science.
[52] M. Nussenzweig,et al. Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir , 2019, The Journal of experimental medicine.
[53] Raul Andino,et al. Mapping the Evolutionary Potential of RNA Viruses. , 2018, Cell host & microbe.
[54] Stefan Elbe,et al. Data, disease and diplomacy: GISAID's innovative contribution to global health , 2017, Global challenges.
[55] R. Sanjuán,et al. Variation in RNA Virus Mutation Rates across Host Cells , 2014, PLoS pathogens.
[56] R. Baric,et al. Coronaviruses , 2011, RNA biology.
[57] S. Plotkin. Correlates of Protection Induced by Vaccination , 2010, Clinical and Vaccine Immunology.
[58] E. Holmes,et al. Rates of evolutionary change in viruses: patterns and determinants , 2008, Nature Reviews Genetics.
[59] S. Elena,et al. The evolution of RNA viruses: A population genetics view. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[60] J. Holland,et al. High nucleotide substitution error frequencies in clonal pools of vesicular stomatitis virus , 1989, Journal of virology.
[61] D. Burnett. Immunoglobulins in the lung. , 1986, Thorax.
[62] J. Holland,et al. Direct method for quantitation of extreme polymerase error frequencies at selected single base sites in viral RNA , 1986, Journal of virology.
[63] R. Andino,et al. Viral quasispecies. , 2015, Virology.